Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 5;22(2):1029-1038.
doi: 10.1007/s40200-023-01279-1. eCollection 2023 Dec.

Engineered probiotics introduced to improve intestinal microecology for the treatment of chronic diseases: present state and perspectives

Jianquan Guo  1   2 , Bangyuan Zhou  2 , Yali Niu  2 , Liangpo Liu  2 , Liyang Yang  3
Affiliations
Review

Engineered probiotics introduced to improve intestinal microecology for the treatment of chronic diseases: present state and perspectives

Jianquan Guo et al. J Diabetes Metab Disord. .

Abstract

Purpose: Correcting intestinal microecological imbalance has become one of the core strategies to treat chronic diseases. Some traditional microecology-based therapies targeting intestine, such as prebiotic therapy, probiotic therapy and fecal microbiota transplantation therapy, have been used in the prevention and treatment of clinical chronic diseases, which still facing low safety and poor controllability problems. The development of synthetic biology technology has promoted the development of intestinal microecology-based therapeutics for chronic diseases, which exhibiting higher robustness and controllability, and become an important part of the next generation of microecological therapy. The purpose of this review is to summarize the application of synthetic biology in intestinal microecology-based therapeutics for chronic diseases.

Methods: The available literatures were searched to find out experimental studies and relevant review articles on the application of synthetic biology in intestinal microecology-based therapeutics for chronic diseases from year 1990 to 2023.

Results: Evidence proposed that synthetic biology has been applied in the intestinal microecology-based therapeutics for chronic diseases, covering metabolic diseases (e.g. diabetes, obesity, nonalcoholic fatty liver disease and phenylketonuria), digestive diseases (e.g. inflammatory bowel disease and colorectal cancer), and neurodegenerative diseases (e.g. Alzheimer's disease and Parkinson's disease).

Conclusion: This review summarizes the application of synthetic biology in intestinal microecology-based therapeutics for major chronic diseases and discusses the opportunities and challenges in the above process, providing clinical possibilities of synthetic biology technology applied in microecological therapies.

Keywords: Chronic diseases; Intestinal metabolites; Microecology-based therapeutics; Probiotics; Synthetic biology.

PubMed Disclaimer

Conflict of interest statement

Competing interestsThe authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Brief schematic diagram of engineered probiotics for the treatment of major chronic diseases
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat reviews Gastroenterol Hepatol. 2017;14(8):491–502. doi: 10.1038/nrgastro.2017.75. - DOI - PubMed
    1. Wilson B, Rossi M, Kanno T, Parkes GC, Anderson S, Mason AJ, et al. beta-galactooligosaccharide in Conjunction with Low FODMAP Diet improves irritable bowel syndrome symptoms but reduces fecal bifidobacteria. Am J Gastroenterol. 2020;115(6):906–15. doi: 10.14309/ajg.0000000000000641. - DOI - PubMed
    1. Lilly DM, Stillwell RH. Probiotics: growth-promoting factors produced by microorganisms. Science. 1965;147(3659):747–8. doi: 10.1126/science.147.3659.747. - DOI - PubMed
    1. Sanders ME, Merenstein DJ, Reid G, Gibson GR, Rastall RA. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nat reviews Gastroenterol Hepatol. 2019;16(10):605–16. doi: 10.1038/s41575-019-0173-3. - DOI - PubMed
    1. Martin R, Miquel S, Benevides L, Bridonneau C, Robert V, Hudault S, et al. Functional characterization of Novel Faecalibacterium prausnitzii strains isolated from healthy volunteers: a Step Forward in the Use of F. prausnitzii as a Next-Generation Probiotic. Front Microbiol. 2017;81226. 10.3389/fmicb.2017.01226. - PMC - PubMed

LinkOut - more resources